Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): A multicentre, randomised, phase 2 trial

The Lancet Oncology

Volumn 14, Issue 4, 2013, Pages 317-326

  Mukherjee, Somnath ^a   Hurt, Christopher N ^b   Bridgewater, John ^c   Falk, Stephen ^d   Cummins, Sebastian ^e   Wasan, Harpreet ^f   Crosby, Tom ^g   Jephcott, Catherine ^h   Roy, Rajarshi ⁱ   Radhakrishna, Ganesh ^j   McDonald, Alec ^k   Ray, Ruby ^b   Joseph, George ^g   Staffurth, John ^b,m   Abrams, Ross A ^l   Griffiths, Gareth ^b,m   Maughan, Tim ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^e ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^f HAMMERSMITH HOSPITAL   (United Kingdom)

^g VELINDRE CANCER CENTRE   (United Kingdom)

^h ADDENBROOKE S HOSPITAL   (United Kingdom)

ⁱ DIANA PRINCESS OF WALES HOSPITAL   (United Kingdom)

^j ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^k BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^l RUSH UNIVERSITY MEDICAL CENTER   (United States)

^m Velindre NHS Trust   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DRUG WITHDRAWAL; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER DISEASE; LIVER DYSFUNCTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; OVERALL SURVIVAL; PANCREAS CANCER; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; SKIN DISEASE; THROMBOCYTE COUNT; THROMBOSIS; THROMBUS; UNITED KINGDOM; VASCULAR DISEASE; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG TOXICITY; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84875783603     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70021-4     Document Type: Article

References (29)

1. Pancreatic cancer statistics Cancer Research UK, (accessed Feb 19, 2013). http://www.cancerresearchuk.org/cancer-info/cancerstats/types/pancreas/?script=true.
2. Hidalgo M Pancreatic cancer. N Engl J Med 2010, 362:1605-1617.
3. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
4. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988, 80:751-755. Gastrointestinal Tumor Study Group.
5. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005, 23:3509-3516.
6. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The gastrointestinal tumor study group. Cancer 1981, 48:1705-1710.
7. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008, 19:1592-1599.
8. Loehrer PJ, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2011, 29:4105-4112.
9. Huguet F, André T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007, 25:326-331.
10. Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007, 110:47-55.
11. Reni M, Cereda S, Balzano G, et al. Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2009, 64:1253-1259.
12. Crane CH, Varadhachary GR, Yordy JS, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 2011, 29:3037-3043.
13. Kim J-S, Lim JH, Kim JH, et al. Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer. Cancer Chemother Pharmacol 2012, 70:381-389.
14. Leone F, Gatti M, Massucco P, et al. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer. Cancer 2013, 119:277-284.
15. Ikeda M, Ioka T, Ito Y, et al. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2013, 85:163-169.
16. Gillmore R, Laurence V, Raouf S, et al. Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience. Clin Oncol (R Coll Radiol) 2010, 22:564-569.
17. Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer 2008, 99:6-13.
18. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26:3487-3495.
19. Li C-P, Chao Y, Chi K-H, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 2003, 57:98-104.
20. Crane CH, Abbruzzese JL, Evans DB, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?. Int J Radiat Oncol Biol Phys 2002, 52:1293-1302.
21. Wilkowski R, Boeck S, Ostermaier S, et al. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer-a multi-centre randomised phase II study. Br J Cancer 2009, 101:1853-1859.
22. Zhu C-P, Shi J, Chen Y-X, Xie W-F, Lin Y Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol 2011, 99:108-113.
23. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009, 27:5513-5518.
24. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
25. Chung HW, Bang SM, Park SW, et al. A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004, 60:1494-1501.
26. Brasiūniene B, Juozaityte E The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer. Medicina (Kaunas) 2007, 43:716-725.
27. Ben-Josef E, Schipper M, Francis IR, et al. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2012, 84:1166-1171.
28. Murphy JD, Adusumilli S, Griffith KA, et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007, 68:801-808.
29. Ogawa K, Ito Y, Hirokawa N, et al. Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival. Int J Radiat Oncol Biol Phys 2012, 83:559-565.